A phase 3 randomized study of radiotherapy plus procarbazine, CCNU, and vincristine (PCV) with or without BUdR for the treatment of anaplastic astrocytoma: a preliminary report of RTOG 9404

This publication has 8 references indexed in Scilit:

• Influence of bromodeoxyuridine radiosensitization on malignant glioma patient survival: A retrospective comparison of survival data from the Northern California Oncology Group (NCOG) and Radiation Therapy Oncology Group trials (RTOG) for glioblastoma multiforme and anaplastic astrocytoma
  International Journal of Radiation Oncology*Biology*Physics, 1998
• Radiation therapy and bromodeoxyuridine chemotherapy followed by procarbazine, lomustine, and vincristine for the treatment of anaplastic gliomas
  International Journal of Radiation Oncology*Biology*Physics, 1995
• Evaluation of bromodeoxyuridine in glioblastoma multiforme: A A Northern California cancer center phase II study
  International Journal of Radiation Oncology*Biology*Physics, 1991
• Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarrazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report
  International Journal of Radiation Oncology*Biology*Physics, 1990
• Enhancement of X ray induced DNA damage by pre-treatment with halogenated pyrimidine analogs
  International Journal of Radiation Oncology*Biology*Physics, 1987
• Phase I study of intravenous bromodeoxyuridine used concomitantly with radiation therapy in patients with primary malignant brain tumors
  International Journal of Radiation Oncology*Biology*Physics, 1984
• Experimental and Clinical Studies of Radiosensitizers in Brain Tumors, with Special Reference to BUdR-Antimetabolite Continuous Regional Infusion-Radiation Therapy (BAR therapy)
  Neurologia medico-chirurgica, 1965
• GENETICS OF HUMAN CELL LINES
  The Journal of Experimental Medicine, 1960